Oral vitamin B6 treatment for PNPO deficiency
Part of Genetic & congenital clinical trials.
This Phase 3 study tests an oral form of vitamin B6 (P5P) to treat PNPO deficiency, a rare genetic condition that can cause seizures. It’s meant for people whose seizures are usually controlled on this treatment, to confirm the best approach going forward.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed PNPO deficiency from genetic testing
- Your seizures are generally controlled with oral P5P taken multiple times per day for at least 30 days
- You are at least 2 years old
- You may join if you previously tried pyridoxine (vitamin B6) and it didn’t work, as long as you’ve been off pyridoxine for at least 24 hours
- You can give consent (or a parent/guardian can if you’re under 18)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether vitamin B6 can help treat inflammatory bowel disease (IBD). It may offer a simple, low-cost option to support your current treatment.
This study tests whether high doses of vitamin B6 can help reduce symptoms of anxiety and depression. If you have mild to moderate anxiety or depression, you may be able to participate.
This study tests whether high doses of vitamin C are safe for people with pyruvate kinase deficiency or G6PD deficiency, two genetic conditions that affect how red blood cells work. Researchers want to see if vitamin C might help, but first they need to confirm it won't cause harm.
This trial is for people who have already completed the Phase 2 study of LP-005 and may continue receiving it. It checks how safe and effective the drug is over a longer period.
This trial tests a new pill called MY008211A for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder where red blood cells are destroyed. If you have moderate anemia and high LDH (a marker of blood cell breakdown), this study may be an option.
This Phase 2 trial studies NM8074 in adults with paroxysmal nocturnal hemoglobinuria (PNH) whose blood counts and breakdown of red blood cells (hemolysis) are not controlled enough on Soliris. NM8074 is meant to reduce the abnormal immune “complement” activity driving the disease and its symptoms like anemia.
Hear when a new Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.